NCT01358409 - Regression of Myocardial Steatosis by Nebivolol | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 1, 2011

Primary Completion Date

February 11, 2013

Study Completion Date

February 11, 2013

Conditions

Cardiac Steatosis and Lipotoxicity

Interventions

DRUG

Nebivolol

Day 1 - Patients will start Nebivolol 5 mg PO daily; after one month, if the subject has tolerated 5 mg PO Nebivolol, the dose will be increased to 10 mg PO daily. If the patients is unable to tolerate 5 mg PO Nebivolol, he/she will be discontinued from the study. After six months, medication will be tapered to 5 mg PO daily for two weeks. Medication will then be tapered to 2.5 mg PO daily for two additional weeks.

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles